Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Apr 18, 2019 in Overactive bladder | 0 comments

In a nutshell

This study compared how safe and effective onabotulinumtoxinA (Botox) and mirabegron are in treating overactive bladder. The authors concluded botox is more effective in the treatment of overactive bladder symptoms.

Some background

Overactive bladder (OAB) is a common syndrome. Symptoms include urinary urgency, frequency, and urine leakage. OAB can affect the patient's quality of life. 

Mirabegron (Myrbetriq) is an OAB medication. It works by relaxing the muscles of the bladder. Botox is injected into the bladder to relieve OAB symptoms.

It is not known if mirabegron or botox, is safer or more effective in the treatment of OAB.

Methods & findings

This report looked at the results of 19 different clinical trials. These clinical trials looked at the use of mirabegron and botox as a treatment for OAB. The patients included in these trials had not been treated successfully by first-line medications. 

Botox was a more effective treatment for OAB symptoms when compared with mirabegron. Patients receiving botox passed urine less often over a 24-hour period. Patients receiving botox also had a reduced number of incontinence (urine leakage) episodes. Neither treatment was more effective at reducing the number of times a patient urinated each night. 

Urinary tract infections were 3.1 times more common in patients treated with Botox compared to mirabegron.

The bottom line

The authors concluded botox is more effective in the treatment of OAB when compared to mirabegron. However, the risk of urinary infections is increased in patients receiving botox

The fine print

This study was funded by Astellas Pharma Global Development, Inc., the manufacturer of mirabegron. 

Published By :


Date :

Feb 19, 2019

Original Title :

The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: A network meta-analysis.

click here to get personalized updates